Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Chonluten
Explore Chonluten, a peptide researched for its impact on lung function and respiratory health.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range1 mcgWeeks 5-6
Recorded example with no verified study backing; shown for amount literacy only.
- Low-mid range4 mcgWeeks 13-14
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range1 mgWeeks 5-6
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Chonluten
What published studies and recent community write-ups report about amounts, timing and course length. 1 preclinical and 5 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical1 row | |||||
| Human monocyte and macrophage cell line (THP-1)THP-1 monocytes and PMA-differentiated THP-1 macrophages | 100 ng/mL, alone or with 100 ng/mL lipopolysaccharide | Single overnight exposure (8 hours of pretreatment for the adhesion assay) | In vitro | One experimentNot applicable | International Journal of Molecular Sciences (PubMed Central)2022 |
| Chonluten was one of five Khavinson peptides tested; with LPS present, IL-6 and TNF release from differentiated macrophages fell for all of them, STAT1 phosphorylation rose, and pretreated monocytes adhered less to LPS-activated endothelial cells. Chonluten alone produced a slight TNF release in resting monocytes and roughly doubled apoptosis compared with the other peptides, and nothing in the study involves lung tissue, animals or people. | |||||
| Community-reported5 rows | |||||
| Vendor-template titration ladder (20 mg vial) | 250 mcg rising to 4,000 mcg (250, 500, 1,000, 1,500, 2,000, 3,000 then 4,000 mcg) | Once daily, stepping up every 2 weeks | Subcutaneous, from a 20 mg vial in 3 mL of bacteriostatic water (6.67 mg/mL) | 8-16 weeksNone described | Community resource2026 |
| A dosage-chart site lays out a 16-week ladder from 250 mcg a day to 4 mg a day, with the syringe units for each step, and its own supply table shows the full course consuming about 12 vials (roughly 227 mg of peptide). The page cites only the THP-1 cell paper for biology and labels the figures educational; the amounts are ten to forty times higher than the other community sources below and have no study behind them. | |||||
| High-dose injectable suggestion and manufacturer capsule course | 5-10 mg by injection; capsules at 1-2 per dose | Once daily by injection; capsules once or twice daily with meals | Subcutaneous, or oral capsules | 12 or more weeks by injection; 10-30 days per capsule courseCapsule courses repeated 2-3 times per year; the page also quotes 10-20 day courses every 3-6 months | Community resource2026 |
| This 2026 profile suggests 5-10 mg once daily for 12 or more weeks while quoting manufacturer instructions of 1-2 capsules once or twice daily for 10-30 days, two or three times a year. The page is internally inconsistent, describing the compound in one section as a cartilage-derived extract and rating its evidence as limited human trials even though it cites no human trial of Chonluten, so its injectable figure should be read as the site's own invention. | |||||
| Oral capsule and sublingual courses | 200-400 mcg (1-2 capsules) daily; 200-400 mcg daily sublingually | Once daily | Oral capsules or sublingual | 10-30 days (capsules); 10-20 days (sublingual)Courses repeated 2-3 times per year | Community resource2026 |
| An evidence-review site lists the retail capsule protocol of 200-400 mcg a day for 10-30 days and a sublingual variant for 10-20 days, often paired with Bronchogen, and states that the amounts are the generic Khavinson supplement framework rather than the result of any Chonluten dose-finding. It notes that no study has compared 200 mcg with 400 mcg or any other dose on any endpoint. | |||||
| Conservative community pattern | 100-200 mcg | Once daily, morning, fasted | Subcutaneous | 10-20 daysNo more than two cycles per year, with 3-6 months between them | Community resource2026 |
| A 2026 guide presents 100-200 mcg a day for a 10-20 day cycle as the most cautious community pattern, extrapolated from the wider Khavinson short-peptide convention, and sets it against the 250-4,000 mcg a day found on dosage calculators and the retail capsule and lingual-drop products. It states plainly that there is no established dose and that the higher community figures have no stronger rationale than the lower ones. | |||||
| Capsule versus research-vial class pattern | 1-2 capsules per day, or 1-2 mg from a research vial | Once daily | Oral capsules (swallowed, about 30 minutes before a meal) or subcutaneous | 10-30 days (capsules); about 10 days (injection)Courses 1-2 times per year | Community resource2026 |
| A dosing-calculator site separates the two products on the market: swallowed Cytomed capsules at 1-2 a day for 10-30 day courses, and reconstituted research vials injected at about 1-2 mg a day for around 10 days. It warns that capsule counts cannot be converted into vial milligrams, that no human pharmacokinetics exist for either, and that the similarly named lung extract Honluten is a different product. | |||||
How a course is commonly described
- Days 1-10Community-reported
Khavinson-style courses start at the full dose with no ramp: 100-200 mcg subcutaneously in the conservative community pattern, 1-2 capsules a day for the retail product, or 1-2 mg a day from a research vial. Guides describe this window as the whole course for injectable use.
- Days 10-30Community-reported
Injectable courses are described as ending at 10-20 days and capsule courses at 30 days. One profile describes subjective respiratory changes in weeks 2-6, during and after the course, without pointing to any measurement.
- Weeks 1-16 (titration template)Community-reported
A separate vendor-template schedule treats Chonluten like a long-course peptide, stepping from 250 mcg a day in weeks 1-2 to 4 mg a day by weeks 13-16 with no break. It is an outlier against the short pulsed courses the rest of the community describes.
- BreakCommunity-reported
The off period is 3-6 months, giving one to three courses a year depending on the guide. The rationale offered is the Khavinson framework's claim that a short course changes tissue gene expression for months, which has not been tested for this peptide in any organism.
- Preclinical comparisonPreclinical
The only measured exposure in the indexed literature is an overnight 100 ng/mL incubation of a monocyte cell line, with or without LPS. There is no animal course and no human course to set the schedules above against.
- None of the courses above has been tested in an animal or a human. The single indexed experiment is a cell line study, so dose, route, course length and the months-long break are all convention.
- Most respiratory claims attached to Chonluten belong to other material: the bronchial epithelium gene study used the tetrapeptide Ala-Asp-Glu-Leu (Bronchogen), and the human chronic bronchitis and COPD statements in the 2020 Khavinson review are referenced to a gastric ulcer gene expression paper rather than to a trial.
- Chonluten is not approved anywhere and no trial is registered. PubChem lists the molecule under Glu-Asp-Gly and T-34 rather than the trade name, and guides warn that the lung extract sold as Honluten is a different product, so a certificate of analysis is the only way to confirm what a vial contains.
Sources for this section (10)
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
- Peptides: Prospects for Use in the Treatment of COVID-19
- Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium
Plus 6 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG, laboratory code T-34), developed in Vladimir Khavinson's bioregulator program as the lung and bronchial peptide and sold as capsules and as lyophilized powder. The only PubMed-indexed paper that uses the name is a 2022 cell study in the human THP-1 monocyte line, run at the University of Chieti-Pescara with Khavinson as co-author, in which Chonluten lowered LPS-driven TNF and IL-6 release and monocyte adhesion to activated endothelium. Khavinson group reviews state that oral EDG helps chronic bronchitis and COPD, but the citation they give for that claim is a 2012 gene expression paper in a gastric ulcer model, and the 2014 bronchial epithelium study often attached to Chonluten concerns a different peptide, the tetrapeptide Ala-Asp-Glu-Leu sold as Bronchogen. No animal dosing study, human trial, pharmacokinetic data or trial registration exists for Chonluten, and it is not approved by any regulator; the courses below are vendor and community conventions.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Gene Regulation & Geroprotection
Insights from short peptide research
- 2
Lung-Focused Research
Anti-inflammatory and mucosal regulation
- 3
Gastrointestinal Studies
Emerging findings outside the lungs
- 4
Summary
Therapeutic takeaways
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Gene Regulation & Geroprotection
Insights from short peptide research
- Not graded
Lung-Focused Research
Anti-inflammatory and mucosal regulation
Amounts recorded for Chonluten
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Weeks 5-6Sign in for schedule, duration and source context.1 mcg
- 2Weeks 13-14Sign in for schedule, duration and source context.4 mcg
- 3Weeks 5-6Sign in for schedule, duration and source context.1 mg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
Glu-Asp-Gly
Also listed as
Glu-Asp-Gly, EDG (code used in the papers), T-34 tripeptide, Glutamyl-aspartyl-glycine, L-Glutamyl-L-aspartyl-glycine, H-Glu-Asp-Gly-OH, CHEBI:162780, DTXSID80996513
InChIKey
DSPQRJXOIXHOHK-WDSKDSINSA-N
IUPAC name
(4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.